We’re proud to have teamed up with the Dolphins Cancer Challenge, the largest fundraising event in the National Football League (NFL), to raise awareness for colorectal cancer screening with our Shield? blood test. This year's event brought together thousands of participants to support innovative cancer research, and we’re grateful to have been part of such a meaningful effort in the fight against cancer.
关于我们
Guardant Health is a leading precision medicine company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, we're transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant Health has commercially launched Guardant360?, Guardant360? CDx, Guardant360 TissueNext?, Guardant360 Response?, and GuardantINFINITY? tests for advanced-stage cancer patients, and Guardant Reveal? for early-stage cancer patients. The Guardant Health screening portfolio, including the FDA-approved Shield? test, aims to address the needs of individuals eligible for cancer screening. Important Note for Job Applicants: Guardant Health is aware of recruiting scams where unauthorized individuals use the company's name in fraudulent emails, job postings, and social media messages. Please note that Guardant Health will never ask for money or credit card information during the job application process, nor does the company communicate with candidates via online chatrooms or personal email accounts such as Gmail or Hotmail.
- 网站
-
https://guardanthealth.com/
Guardant Health的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Palo Alto，California
- 类型
- 上市公司
- 创立
- 2012
地点
Guardant Health员工
动态
-
Today we announced that our Shield? blood test for colorectal cancer screening is now covered by the U.S. Department of Veterans Affairs Community Care Network. With this coverage, veterans age 45 or older at average risk can access Shield with no copay when receiving community care authorized by the VA. “We are proud of the lifesaving value that the Shield blood test can bring to U.S. veterans and their families,” added our co-CEO AmirAli Talasaz. “This coverage decision by the VA is the first for younger and non-Medicare beneficiaries, and we are excited to broaden the impact of our screening test to help detect more colorectal cancer early, when it is most treatable.”
-
Our Shield? blood test has received Advanced Diagnostic Laboratory Test (ADLT) status from the Centers for Medicare & Medicaid Services, showing the unique value of the Shield test for CRC screening. This is another step forward in improving colorectal cancer screening rates and expanding patient access. “We’ve already seen strong adoption by providers with Medicare-covered patient populations. This designation from CMS and a more favorable Medicare rate will help us bring the innovation of Shield to more patients coast-to-coast by accelerating our investments in building our commercial infrastructure," added our co-CEO AmirAli Talasaz.
-
We’re proud to announce a new collaboration with Dak Prescott’s Faith Fight Finish Foundation and the Partners in Wellness program—an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center—to help increase colorectal cancer screening rates in northern and central Louisiana. As part of this effort, the Partners in Wellness mobile screening program will offer our Shield? blood test at events throughout the region during #ColorectalCancerAwarenessMonth, making colorectal cancer screening more accessible and convenient for underserved communities. Together, we’re bringing critical screening options directly to the communities that need them most—because early detection can save lives. More details: https://lnkd.in/e5ucrjmB
-
-
We’re proud to collaborate with the?European Coalition for Comprehensive Genomic Profiling (ECGP) initiative to improve patient access and help make comprehensive genomic profiling (CGP) a routine part of cancer care across Europe!
???Let’s unlock the untapped potential of #ComprehensiveGenomicProfiling (CGP)! We are thrilled to announce the publication of our recommendations on how to improve patient access to CGP:?"The untapped potential of Comprehensive Genomic Profiling"! These recommendations are developed by ECGP in collaboration with their renowned independent experts and patient advocate Steering Group. Patient access to comprehensive genomic profiling across Europe remains limited due to various challenges. Through our recommendations, we outline strategies and actionable insights to address them: ????ECGP recommendations ?? Improve?awareness?on the value of Comprehensive Genomic Profiling (CGP) ?? Establish clear?funding and reimbursement pathways?for technologies like CGP ?? Ensure the?implementation requirements?are realised to ensure patient access to CGP, guidelines, (data) infrastructure, sufficient and capable workforce and stimulating procurement policies. ?? Enhance?collaboration?among policymakers, industry, healthcare professionals, and patient advocacy groups, to improve access to CGP ?? Read the recommendations here: https://lnkd.in/es4eC6ME Join us in our mission to unlock the potential of personalized medicines by increasing access to comprehensive genomic profiling! Feel free to connect with Matias Olsen to further discuss this topic. Find out more about ECGP: https://ecgp.eu/ Amgen Guardant Health Illumina Labcorp Menarini Stemline MSD Vintura #AdvancedDiagnostics #GenomicProfiling #ADx #HealthcareInnovation #ECGP #PatientAccess #EUCOPE #HealthEquity #CGP
-
-
In honor of #ColorectalCancerAwarenessMonth, join us for a special webinar series diving into the latest data from the groundbreaking GOZILA study conducted in Japan. Together, we’ll explore key insights from the 2024 Nature Medicine publication, “Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors” by Nakamura et al., and discuss how this evolving data is shaping the future of precision oncology for colorectal and other gastrointestinal (GI) cancers. ???Webinar Dates & Times: March 11: 12:30pm - 1:00pm ET |?https://bit.ly/41JuxbG March 12: 1:00pm - 1:30pm ET?| https://bit.ly/4ioZ0kM March 12: 7:30pm - 8:00pm ET?| https://bit.ly/4boZGUU March 13: 6:00pm - 6:30pm ET?| https://bit.ly/4irOlpr
-
-
Today marks the start of Colorectal Cancer Awareness Month! A time to come together with partners and communities to support those affected and emphasize the critical role of early detection and screening in the fight against #ColorectalCancer. #ColorectalCancerAwarenessMonth #EarlyDetectionMatters #GetScreened
-
-
Over the past few weeks, our Oncology and Screening teams came together for their annual National Sales Meetings — an incredible opportunity to align on strategy, sharpen skills, and celebrate 2024 achievements. With great energy and a shared focus, our teams are ready to embrace the new year and the opportunities ahead, driven by our mission to conquer cancer with data and a relentless commitment to patients. We’re proud to have such a dedicated team representing Guardant in the field. #ChallengeAccepted #OneGuardant
-
-
Today, we announced findings from our second annual “Closing the Gap: CRC Screening Insights” survey, conducted by The Harris Poll. ? The survey confirms that fear and anxiety about the #ColorectalCancer screening process could keep millions of Americans from getting screened — but it also highlights a promising solution. Both doctors and patients agree that having an FDA-approved blood test option, like Shield?, could help more people complete screening, which could potentially save more lives. Explore the full findings: https://lnkd.in/efJUnENT
-